Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA; The Chemical Biology Program, Harvard University, Cambridge, MA 02138, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA; Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
Trends Cell Biol. 2014 Mar;24(3):179-87. doi: 10.1016/j.tcb.2013.09.011. Epub 2013 Oct 31.
Pioneering work over the past years has highlighted the remarkable ability of manipulating cell states through exogenous, mostly transcription factor-induced reprogramming. The use of small molecules and reprogramming by transcription factors share a common history starting with the early AZA and MyoD experiments in fibroblast cells. Recent work shows that a combination of small molecules can replace all of the reprogramming factors and many previous studies have demonstrated their use in enhancing efficiencies or replacing individual factors. Here we provide a brief introduction to reprogramming followed by a detailed review of the major classes of small molecules that have been used to date and what future opportunities can be expected from these.
在过去的几年中，开创性的工作强调了通过外源性的、主要是转录因子诱导的重编程来操纵细胞状态的非凡能力。小分子的使用和转录因子的重编程有着共同的历史，最早可以追溯到成纤维细胞中 AZA 和 MyoD 的早期实验。最近的工作表明，小分子的组合可以替代所有的重编程因子，许多以前的研究已经证明了它们在提高效率或替代单个因子方面的应用。在这里，我们简要介绍了重编程，然后详细回顾了迄今为止使用的主要类小分子，以及可以预期从这些小分子中获得哪些未来的机会。
